Heparan Sulfate–Editing Extracellular Sulfatases Enhance VEGF Bioavailability for Ischemic Heart Repair
暂无分享,去创建一个
K. Wollert | C. Rudat | M. Korf-Klingebiel | Hauke Schleiner | Xuekun Wu | Stefanie Klede | Y. Mikhed | T. Lübke | Marc R. Reboll | Michael Klintschar | Karsten Grote | Yong Wang | André Nobre | Johann Bauersachs | A. Kispert | Hans W. Niessen | Thomas Dierks
[1] A. Chambery,et al. TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment , 2019, Nucleic acids research.
[2] J. Gogos,et al. EMC10 (Endoplasmic Reticulum Membrane Protein Complex Subunit 10) Is a Bone Marrow–Derived Angiogenic Growth Factor Promoting Tissue Repair After Myocardial Infarction , 2017, Circulation.
[3] Bernd Hertenstein,et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial , 2017, European heart journal.
[4] C. Held,et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014 , 2017, European heart journal.
[5] S. Thorgeirsson,et al. Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. , 2017, Cancer research.
[6] S. Prabhu,et al. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.
[7] Edwin Wu,et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. , 2016, Journal of the American College of Cardiology.
[8] C. Granger,et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.
[9] C. Hodgkinson,et al. Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. , 2016, Circulation research.
[10] T. Dierks,et al. Sulf1 and Sulf2 Differentially Modulate Heparan Sulfate Proteoglycan Sulfation during Postnatal Cerebellum Development: Evidence for Neuroprotective and Neurite Outgrowth Promoting Functions , 2015, PloS one.
[11] C. Moser,et al. Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma , 2015, Hepatology.
[12] A. Ganser,et al. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction , 2015, Nature Medicine.
[13] Doris A Taylor,et al. Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. , 2015, Circulation research.
[14] J. Esko,et al. Demystifying heparan sulfate-protein interactions. , 2014, Annual review of biochemistry.
[15] A. Zeiher,et al. Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. , 2014, European heart journal.
[16] S. Heymans,et al. Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity , 2014, Circulation research.
[17] J. Piek,et al. Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. , 2014, European heart journal.
[18] Aleksander S Popel,et al. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. , 2014, Cytokine & growth factor reviews.
[19] A. Harris,et al. The heparan sulfate editing enzyme Sulf1 plays a novel role in zebrafish VegfA mediated arterial venous identity , 2013, Angiogenesis.
[20] Jun Jiang,et al. Quantitative Phosphoproteomics Analysis Reveals Broad Regulatory Role of Heparan Sulfate on Endothelial Signaling* , 2013, Molecular & Cellular Proteomics.
[21] G. Lip,et al. CXCR4 positive and angiogenic monocytes in myocardial infarction , 2012, Thrombosis and Haemostasis.
[22] G. Jayson,et al. Endothelial Heparan Sulfate 6-O-Sulfation Levels Regulate Angiogenic Responses of Endothelial Cells to Fibroblast Growth Factor 2 and Vascular Endothelial Growth Factor* , 2012, The Journal of Biological Chemistry.
[23] S. Stahl,et al. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. , 2012, Cancer cell.
[24] D. Rowitch,et al. Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma. , 2012, The Journal of clinical investigation.
[25] T. Dierks,et al. Roles of Heparan Sulfate Sulfation in Dentinogenesis* , 2012, The Journal of Biological Chemistry.
[26] M. Masu,et al. Organ-specific Sulfation Patterns of Heparan Sulfate Generated by Extracellular Sulfatases Sulf1 and Sulf2 in Mice* , 2012, The Journal of Biological Chemistry.
[27] Lu Cao,et al. hSulf-1 Gene Exhibits Anticancer Efficacy through Negatively Regulating VEGFR-2 Signaling in Human Cancers , 2011, PloS one.
[28] J. Esko,et al. Heparan sulfate proteoglycans. , 2011, Cold Spring Harbor perspectives in biology.
[29] Yuquan Wei,et al. SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo , 2011, Clinical Cancer Research.
[30] Chi-Huey Wong,et al. Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways , 2010, Proceedings of the National Academy of Sciences.
[31] A. Zeiher,et al. CXCR4 Expression Determines Functional Activity of Bone Marrow–Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[32] A. Ganser,et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. , 2008, European heart journal.
[33] T. Dierks,et al. Sulf Loss Influences N-, 2-O-, and 6-O-Sulfation of Multiple Heparan Sulfate Proteoglycans and Modulates Fibroblast Growth Factor Signaling* , 2008, Journal of Biological Chemistry.
[34] C. Glass,et al. Surfen, a small molecule antagonist of heparan sulfate , 2008, Proceedings of the National Academy of Sciences.
[35] S. Rafii,et al. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. , 2007, Trends in immunology.
[36] M. Tessier-Lavigne,et al. Secreted Sulfatases Sulf1 and Sulf2 Have Overlapping yet Essential Roles in Mouse Neonatal Survival , 2007, PloS one.
[37] T. Dierks,et al. Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. , 2006, The Biochemical journal.
[38] J. Chien,et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. , 2006, Cancer research.
[39] L. Claesson‐Welsh,et al. VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.
[40] Christopher J. Robinson,et al. VEGF165-binding Sites within Heparan Sulfate Encompass Two Highly Sulfated Domains and Can Be Liberated by K5 Lyase* , 2006, Journal of Biological Chemistry.
[41] J. Gallagher,et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 , 2006, BMC Biochemistry.
[42] K. Kimata,et al. Heparin Regulates Vascular Endothelial Growth Factor165-dependent Mitogenic Activity, Tube Formation, and Its Receptor Phosphorylation of Human Endothelial Cells , 2005, Journal of Biological Chemistry.
[43] A. Ganser,et al. Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium , 2005, Circulation.
[44] L. Claesson‐Welsh,et al. The Adaptor Protein Shb Binds to Tyrosine 1175 in Vascular Endothelial Growth Factor (VEGF) Receptor-2 and Regulates VEGF-dependent Cellular Migration* , 2004, Journal of Biological Chemistry.
[45] Z. Werb,et al. Cloning and Characterization of Two Extracellular Heparin-degrading Endosulfatases in Mice and Humans* , 2002, The Journal of Biological Chemistry.
[46] R. Brekken,et al. Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.
[47] T. Ruzicka,et al. [Granulomatous allergic reaction of the delayed type to surfen]. , 1981, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[48] S. Fisher,et al. Stem cell treatment for acute myocardial infarction. , 2012, The Cochrane database of systematic reviews.